WebAfirma® Genomic Test for Thyroid Nodules Ask for the thyroid nodule test that reveals more about you. WebJul 18, 2024 · Background: The Afirma Gene Expression Classifier (GEC) has been used to further characterize cytologically indeterminate (cyto-I) thyroid nodules into either benign or suspicious categories. However, its relatively low positive predictive value (PPV) limited its use as a classifier for patients with suspicious results. The Afirma Gene …
Afirma Genomic Sequencing Classifier (GSC) » Incyte …
WebThe Afirma Genomic Sequencing Classifier (GSC) provides physicians with a comprehensive solution for a complex landscape in thyroid cancer diagnosis and … WebMay 26, 2024 · The Afirma Genomic Sequencing Classifier (GSC) had been used to classify samples as benign or suspicious following an indeterminate result by cytopathology (Bethesda III-IV). Researchers... hallmark life insurance co
Performance of afirma gene sequencing classifier versus gene express…
WebJul 5, 2024 · Data on Afirma’s genomic sequencing classifier (GSC) performance in atypia of undetermined significance (AUS) subcategories is limited. This study investigated GSC performance in AUS nodules with architectural atypia (AUS-A), cytological atypia (AUS-C), architectural and cytological atypia (AUS-AC), and predominantly Hürthle cells … WebVermont Informed Consent for Genetic Testing . Test Documents ... Test Code AFIRMA AFIRMA GENOMIC SEQUENCING CLASSIFIER FOR INDETERMINATE THYROID … WebApr 24, 2024 · The Afirma Genomic Sequencing Classifier (GSC) is a rule-out test for malignancy/noninvasive follicular thyroid neoplasms with papillary-like nuclear features among patients with Bethesda category III/IV nodules, whereas the complimentary Xpression Atlas provides genomic insights from a curated panel of 511 genes among … hallmark licensing inc